Sean Studer

This inventor holds 1 USPTO granted patent. Top assignee: Adarx Pharmaceuticals, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sean Studer. Retrieved from https://idiyas.com/inventor/sean-studer-uyq3pys4

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Sean Studer: Innovator in Complement Factor B-Modulating Compositions

Introduction

Sean Studer is a notable inventor recognized for his contributions to the field of pharmaceuticals. He is currently associated with Adarx Pharmaceuticals, Inc., where he focuses on innovative solutions in medical science. His work has led to the development of significant patents that aim to enhance therapeutic methods.

Latest Patents

Sean Studer holds a patent for "Complement Factor B-Modulating Compositions and Methods of Use Thereof." This patent represents a crucial advancement in the understanding and application of complement factor modulation, which has implications for various medical treatments. He has 1 patent to his name, showcasing his commitment to innovation in the pharmaceutical industry.

Career Highlights

Throughout his career, Sean has demonstrated a strong dedication to research and development. His role at Adarx Pharmaceuticals, Inc. has allowed him to collaborate with other experts in the field, further enhancing his contributions to medical science. His innovative mindset and technical expertise have positioned him as a valuable asset in the industry.

Collaborations

Sean has worked closely with Rui Zhu, a fellow professional in the pharmaceutical sector. Their collaboration has fostered an environment of creativity and innovation, leading to advancements in their respective fields.

Conclusion

Sean Studer is a prominent inventor whose work in complement factor modulation is paving the way for new therapeutic methods. His contributions to Adarx Pharmaceuticals, Inc. and the pharmaceutical industry as a whole are commendable.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…